JPWO2022150911A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022150911A5 JPWO2022150911A5 JP2023541702A JP2023541702A JPWO2022150911A5 JP WO2022150911 A5 JPWO2022150911 A5 JP WO2022150911A5 JP 2023541702 A JP2023541702 A JP 2023541702A JP 2023541702 A JP2023541702 A JP 2023541702A JP WO2022150911 A5 JPWO2022150911 A5 JP WO2022150911A5
- Authority
- JP
- Japan
- Prior art keywords
- pharma
- group
- acceptable salt
- compound
- ceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 23
- 150000003839 salts Chemical class 0.000 claims 20
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 14
- 229910052736 halogen Inorganic materials 0.000 claims 9
- 150000002367 halogens Chemical class 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- -1 -CF 3 Chemical group 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 claims 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 claims 1
- 208000005870 Lafora disease Diseases 0.000 claims 1
- 208000014161 Lafora myoclonic epilepsy Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 101150082971 Sgk1 gene Proteins 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 230000009787 cardiac fibrosis Effects 0.000 claims 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000037906 ischaemic injury Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 208000004731 long QT syndrome Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163136782P | 2021-01-13 | 2021-01-13 | |
| US63/136,782 | 2021-01-13 | ||
| US202163262040P | 2021-10-04 | 2021-10-04 | |
| US63/262,040 | 2021-10-04 | ||
| PCT/CA2022/050038 WO2022150911A1 (en) | 2021-01-13 | 2022-01-12 | Pyrazolo[3,4-d]pyrimidin-6-yl-sulfonamide derivatives for the inhibition of sgk-1 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024502178A JP2024502178A (ja) | 2024-01-17 |
| JP2024502178A5 JP2024502178A5 (https=) | 2025-01-17 |
| JPWO2022150911A5 true JPWO2022150911A5 (https=) | 2025-01-17 |
Family
ID=82446316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023541702A Pending JP2024502178A (ja) | 2021-01-13 | 2022-01-12 | Ｓｇｋ－１を阻害するためのピラゾロ［３，４－ｄ］ピリミジン－６－イル－スルホンアミド誘導体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240309005A1 (https=) |
| EP (1) | EP4277905A4 (https=) |
| JP (1) | JP2024502178A (https=) |
| KR (1) | KR20230136622A (https=) |
| CN (1) | CN121517419A (https=) |
| AU (1) | AU2022208639A1 (https=) |
| MX (1) | MX2023008219A (https=) |
| WO (1) | WO2022150911A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250085708A (ko) * | 2022-07-12 | 2025-06-12 | 쓰리브 테라퓨틱스 인크. | N-[4-[4-[[2-(디메틸아미노)에틸]아미노]-3-메틸-1H-피라졸로[3,4-d]피리미딘-6-일)-2-플루오로페닐]-2,5-디플루오로벤젠설폰아미드의염 및 이의 결정 형태 |
| WO2024015055A1 (en) * | 2022-07-13 | 2024-01-18 | Thryv Therapeutics Inc. | Pyrazolo[3,4-d]pyrimidin-6-yl-sulfonamide derivatives for the inhibition of sgk-1 and treatment of cancer |
| KR102912267B1 (ko) * | 2023-04-20 | 2026-01-15 | 한국화학연구원 | 신규한 헤테로고리 화합물 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 포함하는 바이러스성 질환의 예방 또는 치료용 약학적 조성물 |
| CN121909195A (zh) * | 2023-09-27 | 2026-04-21 | 百时美施贵宝公司 | 作为sgk1抑制剂的哌啶取代的吡唑并嘧啶衍生物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5827849B2 (ja) * | 2011-09-20 | 2015-12-02 | サノフイ | Ｎ−［４−（１Ｈ−ピラゾロ［３，４−ｂ］ピラジン−６−イル）−フェニル］−スルホンアミド及び薬剤としてのその使用 |
| TWI629275B (zh) * | 2013-03-13 | 2018-07-11 | 賽諾菲公司 | Ｎ－（４－（氮雜吲唑－６－基）－苯基）－磺醯胺及其作為醫藥之用途 |
| PT3049085T (pt) * | 2013-09-26 | 2021-10-01 | Beth Israel Deaconess Medical Ct Inc | Inibidores de sgk1 no tratamento da síndrome do qt longo |
| US11236083B2 (en) * | 2016-12-07 | 2022-02-01 | Orimos Therapeutics Co., Ltd. | Compounds and pharmaceutical compositions for modulating SGK activity, and methods thereof |
-
2022
- 2022-01-12 US US18/272,162 patent/US20240309005A1/en active Pending
- 2022-01-12 WO PCT/CA2022/050038 patent/WO2022150911A1/en not_active Ceased
- 2022-01-12 MX MX2023008219A patent/MX2023008219A/es unknown
- 2022-01-12 JP JP2023541702A patent/JP2024502178A/ja active Pending
- 2022-01-12 KR KR1020237027620A patent/KR20230136622A/ko active Pending
- 2022-01-12 EP EP22738863.4A patent/EP4277905A4/en active Pending
- 2022-01-12 AU AU2022208639A patent/AU2022208639A1/en active Pending
- 2022-01-12 CN CN202511808384.4A patent/CN121517419A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022121594A5 (https=) | ||
| JP7326622B2 (ja) | Ｅｒｋ阻害剤としてのスピロ系化合物およびその使用 | |
| JP2019529444A5 (https=) | ||
| JP6087367B2 (ja) | 三環式化合物、それらを含む組成物およびそれらの使用 | |
| JP2007527919A5 (https=) | ||
| JP2014077003A5 (https=) | ||
| JP2019530724A5 (https=) | ||
| JP2015508068A5 (https=) | ||
| CN102083773A (zh) | {f-19}标记的l-谷氨酸和l-谷氨酰胺衍生物(ⅲ)、其用途和制备方法 | |
| JP2020111571A5 (https=) | ||
| US8440675B2 (en) | Potentiator of radiation therapy | |
| JP2021530554A5 (https=) | ||
| EP2643301B1 (fr) | Complexe de technetium 99m en tant qu'outil de diagnostic in vivo des tumeurs cancereuses | |
| JPWO2022150911A5 (https=) | ||
| Schilling et al. | Paroxysmal atrial flutter suppressed by repair of a large paraesophageal hernia | |
| JPWO2022221227A5 (https=) | ||
| JP2018507207A5 (https=) | ||
| JPWO2021026180A5 (https=) | ||
| KR101920902B1 (ko) | 심혈관 질환 조기진단 pet 조영용 화합물 및 그의 용도 | |
| JPWO2022020730A5 (https=) | ||
| JPH06509803A (ja) | 抗不整脈及び抗細動剤として有用な新規環状尿素類 | |
| KR101763740B1 (ko) | 탄소환 뉴클레오시드 및 이들의 약학적 용도 및 조성물 | |
| JPWO2019200314A5 (https=) | ||
| JPH1067733A5 (https=) | ||
| JPWO2020219417A5 (https=) |